Patrica Engel McGoldrick

Mrs. Patrica Engel McGoldrick

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Trials
Verified
Journal Article
Open access
PDF file
JOJacqueline A. Odgis
Jacqueline A. Odgis
KGKatie M. Gallagher
Katie M. Gallagher
Sabrina SuckielSabrina Suckiel
Sabrina Suckiel
KDKatherine E. Donohue
Katherine E. Donohue
MRMichelle A. Ramos
Michelle A. Ramos
EKEimear E Kenny
Eimear E Kenny
Background: Increasingly, genomics is informing clinical practice, but challenges remain for medical professionals lacking genetics expertise, and in access to and clinical utility of genomic testing for minority and underrepresented populations. The latter is a particularly pernicious problem due to the historical lack of inclusion of racially and ethnically diverse populations in genomic research and genomic medicine. A further challenge is the rapidly changing landscape of genetic tests and considerations of cost, interpretation, and diagnostic yield for emerging modalities like whole-genome sequencing. Methods: The NYCKidSeq project is a randomized controlled trial recruiting 1130 children and young adults predominantly from Harlem and the Bronx with suspected genetic disorders in three disease categories: neurologic, cardiovascular, and immunologic. Two clinical genetic tests will be performed for each participant, either proband, duo, or trio whole-genome sequencing (depending on sample availability) and proband targeted gene panels. Clinical utility, cost, and diagnostic yield of both testing modalities will be assessed. This study will evaluate the use of a novel, digital platform (GUÍA) to digitize the return of genomic results experience and improve participant understanding for English- and Spanish-speaking families. Surveys will collect data at three study visits: baseline (0 months), result disclosure visit (ROR1, + 3 months), and follow-up visit (ROR2, + 9 months). Outcomes will assess parental understanding of and attitudes toward receiving genomic results for their child and behavioral, psychological, and social impact of results. We will also conduct a pilot study to assess a digital tool called GenomeDiver designed to enhance communication between clinicians and genetic testing labs. We will evaluate GenomeDiver’s ability to increase the diagnostic yield compared to standard practices, improve clinician’s ability to perform targeted reverse phenotyping, and increase the efficiency of genetic testing lab personnel. Discussion: The NYCKidSeq project will contribute to the innovations and best practices in communicating genomic test results to diverse populations. This work will inform strategies for implementing genomic medicine in health systems serving diverse populations using methods that are clinically useful, technologically savvy, culturally sensitive, and ethically sound. Trial registration: ClinicalTrials.gov NCT03738098. Registered on November 13, 2018 Trial Sponsor: Icahn School of Medicine at Mount Sinai Contact Name: Eimear Kenny, PhD (Principal Investigator) Address: Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl., Box 1003, New York, NY 10029 Email: eimear.kenny@mssm.edu

21 May 2019 in Epilepsia
Verified
Journal Article
Closed access
PDF file
KBKristen Barbour
Kristen Barbour
DHDale C. Hesdorffer
Dale C. Hesdorffer
NTNiu Tian
Niu Tian
EYElissa G. Yozawitz
Elissa G. Yozawitz
PMPatrica Engel McGoldrick
Patrica Engel McGoldrick
ZGZachary M. Grinspan
Zachary M. Grinspan

1 April 2021 in Epilepsy & Behavior
Verified
Journal Article
Closed access
KBKristen Barbour
Kristen Barbour
EYElissa G. Yozawitz
Elissa G. Yozawitz
PMPatrica Engel McGoldrick
Patrica Engel McGoldrick
SWSteven Wolf
Steven Wolf
ANAaron Nelson
Aaron Nelson
ZGZachary M. Grinspan
Zachary M. Grinspan

1 September 2024 in Epilepsy & Behavior
Verified
Journal Article
Open access
CBCameron P. Beaudreault
Cameron P. Beaudreault
SCSharon Chiang
Sharon Chiang
ASAriel Sacknovitz
Ariel Sacknovitz
RMRobert Moss
Robert Moss
PBPaige Brabant
Paige Brabant
SWSteven Wolf
Steven Wolf
To assess the impact of vagus nerve stimulation (VNS) on quality of life contributors such as rescue medications. Using the seizure diary application SeizureTracker™ database, we examined trends in rescue administration frequency before and after the first recorded VNS magnet swipe in patients with drug-resistant epilepsy who had 1) At least one VNS magnet swipe recorded in the diary, and 2) Recorded usage of a benzodiazepine rescue medication (RM) within 90 days prior to the first swipe. A paired Wilcoxon rank-sum test was used to assess changes in RM usage frequency between 30-, 60-, 90-, 180- and 360-day intervals beginning 30 days after first magnet swipe. Longitudinal changes in RM usage frequency were assessed with a generalized estimating equation model. We analyzed data of 95 patients who met the inclusion criteria. Median baseline seizure frequency was 8.3 seizures per month, with median baseline rescue medication usage frequency of 2.1 administrations per month (SD 3.3). Significant reductions in rescue medication usage were observed in the 91 to 180 day interval after first VNS magnet swipe, and at 181 to 360 days and at 361 to 720 days, with the magnitude of reduction increasing over time. Decreases in rescue medication usage were sustained when controlling for patients who did not record rescue medication use after the first VNS magnet swipe (N=91). Significant predictors of reductions in rescue medication included baseline frequency of rescue medication usage and time after first VNS magnet swipe. This retrospective analysis suggests that usage of rescue medications is reduced following the start of VNS treatment in patients with epilepsy, and that the magnitude of reduction may progressively increase over time.

10 May 2024 in Epilepsia Open
Verified
Journal Article
Open access
SWSteven Wolf
Steven Wolf
DBDanielle Boyce
Danielle Boyce
PPPatricia Peña
Patricia Peña
JPJesus Eric Piña‐Garza
Jesus Eric Piña‐Garza
JRJessica J. Roland
Jessica J. Roland
PMPatrica Engel McGoldrick
Patrica Engel McGoldrick
Objective: To evaluate the Refractory Epilepsy Screening Tool for Lennox–Gastaut Syndrome (REST‐LGS) for real‐world identification of LGS in adults and to develop a scoring system for the tool.Methods: A retrospective chart review of adults with drug resistant epilepsy (DRE) and intellectual development disorder (IDD) was conducted by 2 primary care providers blinded to diagnosis. The REST‐LGS was designed via the Modified Delphi Consensus and was previously validated. This tool consists of 8 criteria (4 major, 4 minor) considered indicative of LGS. To account for missing data in the earlier validation study and to evaluate applicability in a real‐world setting, the REST‐LGS was refined to include a scoring system in which major criteria were more heavily weighted than minor criteria, producing categories of “likely” (>11 points), “possible” (8–11 points), and “unlikely” (<8 points) LGS. Statistical analyses were descriptive.Results: Of the 100 patients included in the analysis, data for slow spike–waves in electroencephalography and seizure onset age – both major REST‐LGS criteria – were missing for 46% and 42% of patients, respectively. The majority of patients met 4 of the 8 REST‐LGS criteria (cognitive impairment since childhood, 71%; persistent seizures despite a trial of ≥2 antiseizure medications, 65%; seizure onset before the age of 12 years, 57%; ≥2 seizure types, 56%). All 4 major criteria were met in 22 patients (22%). The percentages of patients considered “likely,” “possible,” or “unlikely” to have LGS were 26%, 30%, and 44%, respectively. Of the 74 patients without a previous LGS diagnosis, 42 (57%) were identified as “possible” or “likely” to have LGS using REST‐LGS.Significance: In this analysis, the validated REST‐LGS was evaluated in a real‐world setting. The majority of previously undiagnosed patients were identified via REST‐LGS as “possible” or “likely” to have LGS. Extensive missing data highlights challenges of LGS diagnosis in adults.Plain Language Summary: There is a need to identify adult patients with Lennox–Gastaut syndrome (LGS) so they can receive appropriate treatment. The Refractory Epilepsy Screening Tool for LGS (REST‐LGS) questionnaire was designed by experts to identify whether patients with seizures that are not controlled by medications may have LGS. In this study, 2 physicians completed the REST‐LGS using charts for 100 patients who experience seizures not controlled by medications. Of the patients who were previously diagnosed as not having LGS, the majority were “likely” or “possible” to have LGS based on the REST‐LGS; therefore, the REST‐LGS can identify patients for further evaluation.

16 October 2024 in Brain Sciences
Verified
Journal Article
Open access
PDF file
CBCameron P. Beaudreault
Cameron P. Beaudreault
RWRichard Wang
Richard Wang
CMCarrie R Muh
Carrie R Muh
ARAshley Rosenberg
Ashley Rosenberg
AFAbigail Funari
Abigail Funari
SCSangmi Park & Sangmi Chung
Sangmi Park & Sangmi Chung
Background: Cell-based therapies for drug-resistant epilepsy using induced pluripotent stem cell-derived inhibitory interneurons are now in early-phase clinical trials, building on findings from trials in Parkinson’s disease (PD) and Huntington’s disease (HD). Graft rejection and the need for immunosuppressive therapy post-transplantation pose potential barriers to more epilepsy patients becoming potential candidates for inhibitory interneurons transplantation surgery. Objectives: The present literature review weighs the evidence for and against human leukocyte antigen (HLA)-mediated graft rejection in PD and HD and examines the potential advantages and drawbacks to five broad approaches to cell-based therapies, including autologous cell culture and transplantation, in vivo reprogramming of glial cells using viral vectors, allogeneic transplantation using off-the-shelf cell lines, transplantation using inhibitory interneurons cultured from HLA-matched cell lines, and the use of hypoimmunogenic-induced pluripotent stem cell-derived inhibitory interneurons. The impact of surgical technique and associated needle trauma on graft rejection is also discussed. Methods: Non-systematic literature review. Results: While cell-based therapies have enjoyed early successes in treating a host of central nervous system disorders, the immunologic reaction against surgical procedures and implanted materials has remained a major obstacle. Conclusions: Adapting cell-based therapies using iPSC-derived inhibitory interneurons for epilepsy surgery will similarly require surmounting the challenge of immunogenicity.